139 related articles for article (PubMed ID: 19419757)
21. Losac, a factor X activator from Lonomia obliqua bristle extract: its role in the pathophysiological mechanisms and cell survival.
Alvarez Flores MP; Fritzen M; Reis CV; Chudzinski-Tavassi AM
Biochem Biophys Res Commun; 2006 May; 343(4):1216-23. PubMed ID: 16597435
[TBL] [Abstract][Full Text] [Related]
22. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
Langer F; Spath B; Haubold K; Holstein K; Marx G; Wierecky J; Brümmendorf TH; Dierlamm J; Bokemeyer C; Eifrig B
Ann Hematol; 2008 Jun; 87(6):451-7. PubMed ID: 18292996
[TBL] [Abstract][Full Text] [Related]
23. Proaggregating and procoagulant activities of human mesothelioma tumor cells at different stages of "in vitro" culture.
Pacchiarini L; Meloni F; Zucchella M; Mangiarotti P; Tacconi F; Ballabio P; Grignani G
Haematologica; 1991; 76(5):392-7. PubMed ID: 1806443
[TBL] [Abstract][Full Text] [Related]
24. A factor X-activating cysteine protease from malignant tissue.
Gordon SG; Cross BA
J Clin Invest; 1981 Jun; 67(6):1665-71. PubMed ID: 7016920
[TBL] [Abstract][Full Text] [Related]
25. The prothrombotic state in cancer: pathogenic mechanisms.
De Cicco M
Crit Rev Oncol Hematol; 2004 Jun; 50(3):187-96. PubMed ID: 15182825
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells.
Napoleone E; Zurlo F; Latella MC; Amore C; Di Santo A; Iacoviello L; Donati MB; Lorenzet R
Eur J Cancer; 2009 Feb; 45(3):470-7. PubMed ID: 19046877
[TBL] [Abstract][Full Text] [Related]
27. [Assessment of the efficacy of cancer procoagulant (CP) activity evaluation in the oncological diagnosis of the urinary system].
Szajda SD; Darewicz B; Kudelski J; Werel T; Zwierz K; Skrzydlewski Z; Gabrylewski W
Pol Merkur Lekarski; 2005 Oct; 19(112):596-9. PubMed ID: 16379335
[TBL] [Abstract][Full Text] [Related]
28. Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.
Rousseau A; Larsen AK; Van Dreden P; Sabbah M; Elalamy I; Gerotziafas GT
Int J Oncol; 2017 Dec; 51(6):1747-1756. PubMed ID: 29075790
[TBL] [Abstract][Full Text] [Related]
29. Procoagulant properties of human MV3 melanoma cells.
Geaquinto DL; Fernandes RS; Lima LG; Barja-Fidalgo C; Monteiro RQ
Braz J Med Biol Res; 2008 Feb; 41(2):99-105. PubMed ID: 18235964
[TBL] [Abstract][Full Text] [Related]
30. [Establishment and characterization of a human squamous cell carcinoma cell line LK-52 which produce direct activator of coagulant factor X].
Inufusa H; Hara S; Mori N; Yasutomi M
Hum Cell; 1992 Sep; 5(3):287-91. PubMed ID: 1467328
[TBL] [Abstract][Full Text] [Related]
31. Effect of immunisation with cancer procoagulant on the growth of Walker 256 carcinosarcoma cells in rats.
Kamocka M; Kaplinska K; Mielicki WP
Clin Exp Med; 2006 Oct; 6(3):119-23. PubMed ID: 17061060
[TBL] [Abstract][Full Text] [Related]
32. A novel anti-tissue factor monoclonal antibody with anticoagulant potency derived from synthesized multiple antigenic peptide through blocking FX combination with TF.
Peng ZC; Cai X; Zhang YG; Kong DS; Guo HS; Liang W; Tang QQ; Song HY; Ma D
Thromb Res; 2007; 121(1):85-93. PubMed ID: 17573098
[TBL] [Abstract][Full Text] [Related]
33. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.
Rucińska M; Furman M; Skrzydlewski Z; Zaremba E
Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361
[TBL] [Abstract][Full Text] [Related]
34. Procoagulant factors in patients with cancer.
Molnar S; Guglielmone H; Lavarda M; Rizzi ML; Jarchum G
Hematology; 2007 Dec; 12(6):555-9. PubMed ID: 17852460
[TBL] [Abstract][Full Text] [Related]
35. Evidence of a warfarin-sensitive cancer procoagulant in V2 carcinoma.
Roncaglioni MC; Falanga A; D'Alessandro AP; Alessio MG; Casali B; Donati MB
Haematologica; 1989; 74(2):143-7. PubMed ID: 2501168
[TBL] [Abstract][Full Text] [Related]
36. Procoagulant activity and phosphatidylserine of amniotic fluid cells.
Zhou J; Liu S; Ma M; Hou J; Yu H; Lu C; Gilbert GE; Shi J
Thromb Haemost; 2009 May; 101(5):845-51. PubMed ID: 19404537
[TBL] [Abstract][Full Text] [Related]
37. In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.
Krause J; Frost CL
Protein J; 2018 Apr; 37(2):151-163. PubMed ID: 29411223
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of diagnostic values of neoplastic procoagulant in pancreatic, hepatic and ovary cancers].
Snarska J; Szajda S; Skrzydlewski Z; Kozuszko B
Pol Merkur Lekarski; 2003 Aug; 15(86):123-4. PubMed ID: 14648973
[TBL] [Abstract][Full Text] [Related]
39. Macrophages synthesize factor X and secrete factor X/Xa-containing prothrombinase activity into the surrounding medium.
Pejler G; Lunderius C; Tomasini-Johansson B
Thromb Haemost; 2000 Sep; 84(3):429-35. PubMed ID: 11019967
[TBL] [Abstract][Full Text] [Related]
40. A proteolytic procoagulant associated with malignant transformation.
Gordon SG
J Histochem Cytochem; 1981 Mar; 29(3A Suppl):457-63. PubMed ID: 7016982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
